{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-025443","form_type":"8-K","ticker":null,"cik":"0001169987","company_name":"HTG MOLECULAR DIAGNOSTICS, INC","filed_at":"2022-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.801897+00:00","generated_at":"2026-06-21T15:41:10.732591+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"HTG Molecular receives Nasdaq delisting notice for stockholders' equity below $2.5M","bullets":["Nasdaq notified HTG Molecular on Nov 18, 2022 for non-compliance due to stockholders' equity falling below $2.5M as of Sept 30, 2022.","Company has 45 calendar days, until Jan 2, 2023, to submit a plan to regain compliance with Nasdaq Rule 5550(b).","If plan accepted, Nasdaq may grant up to 180-day extension from Notice date for evidence of compliance.","No assurance that the Company will be able to regain compliance with the continued listing standard."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-025443","json":"https://secwatch.observer/filing/0000950170-22-025443.json","markdown":"https://secwatch.observer/filing/0000950170-22-025443.md","text":"https://secwatch.observer/filing/0000950170-22-025443.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1169987/000095017022025443/0000950170-22-025443-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1169987/000095017022025443/htgm-20221118.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T15:41:10.732591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ad1767f67b59bb82ab8077a48281fb528a9d05d3","claim":"HTG MOLECULAR DIAGNOSTICS, INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)).","evidence_excerpt":"November 18, 2022, HTG Molecular Diagnostics, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that, as a result of the Company’s stockholders’ equity falling below $2.5 million, as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, the Company does not satisfy one of The Nasdaq Capital Market continued listing requirement set forth in Nasdaq Stock Market Rule 5550(b) (the “Rule”). Pursuant to the Notice and Nasdaq rules, the Company has 45 calendar days, or until January 2, 2023, to submit a plan to","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1169987/000095017022025443/0000950170-22-025443-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}